Home » Rigel Hit By Asthma Drug Failure
Rigel Hit By Asthma Drug Failure
Rigel’s SKY inhibitor R343, intended to treat asthma, failed to meet both of its endpoints in a mid-stage clinical trial. The company’s stock dropped nearly 20 percent upon announcement of the unfavorable results.
Pharma Times
Pharma Times
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct